iBio, Inc. announced its financial results for the first quarter of fiscal year 2027, which ended September 30, 2026. The company reported revenues of approximately $1.1 million for the quarter, representing an increase of $1.0 million compared to the same period in the prior year. During this period, the company reported a net loss of $7.6 million, or $0.05 per share, compared to a net loss of $5.7 million, or $0.11 per share, in the prior year.
Research and development expenses for the three months ended September 30, 2026, totaled approximately $6.7 million, an increase of approximately $3.1 million, or 87%, compared to the prior year. The company attributed this increase to higher spending on consultants and outside services supporting R&D efforts, including the IBIO-600 Phase 1 human clinical trial, non-human primate studies, and chemical manufacturing and controls (CMC) activities. General and administrative expenses were approximately $2.8 million, an increase of approximately $0.3 million, or 10%, compared to the prior year, primarily due to increased personnel costs and legal fees.
In terms of clinical progress, iBio presented additional preclinical data for its long-acting Activin E antibody, IBIO-610, at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026. The data, derived from a study in obese non-human primates, showed that at week eight, fat accounted for 93% of the weight lost by NHPs receiving IBIO-610 in combination with semaglutide, compared to 77% for NHPs receiving semaglutide alone. The company expects to initiate first-in-human trials of IBIO-610 in the first half of 2027.
Additionally, iBio completed dosing in the single ascending dose portion of the first-in-human Phase 1 clinical trial of IBIO-600, a long-acting anti-myostatin antibody. The company anticipates interim data from this study in the first quarter of 2027 and plans to begin the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027.
As of September 30, 2026, iBio held cash and cash equivalents and investments in debt securities totaling approximately $76.7 million. The company also plans to participate in several upcoming scientific and investor conferences, including the Guggenheim Healthcare Innovation Conference, ObesityWeek 2026, and the Jefferies Global Healthcare Conference.
